[{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"CellResearch Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellResearch Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CellResearch Corporation \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by CellResearch Corporation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell

                          Therapeutic Area : Podiatry

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : CorLiCyte® is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions.

                          Product Name : CorLiCyte

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 16, 2022

                          Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank